A randomized controlled trial comparing pramipexole with levodopa in early Parkinson's disease: Design and methods of the CALM-PD study

Clinical Neuropharmacology

Volumn 23, Issue 1, 2000, Pages 34-44

  Holloway, Robert ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

Cost effectiveness analysis; Levodopa; Parkinson's disease; Pramipexole; Quality of life; Randomized clinical trial

Indexed keywords

LEVODOPA; PRAMIPEXOLE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSKINESIA; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PARKINSON DISEASE; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ANTIPARKINSON AGENTS; BENZOTHIAZOLES; COST-BENEFIT ANALYSIS; DOPAMINE AGONISTS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; LEVODOPA; MALE; MIDDLE AGED; PARKINSON DISEASE; QUALITY OF LIFE; THIAZOLES; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TREATMENT OUTCOME;

EID: 0033960907     PISSN: 03625664     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002826-200001000-00007     Document Type: Article

References (42)

1. Fahn S. Adverse effects of levodopa. In: Olanow CW, Lieberman AN, eds. The Scientific Basis for the Treatment of Parkinson's Disease. Carnforth, England: Parthenon Publishing Group; 1992:89-112.
2. Agid Y. Levodopa: is toxicity a myth? Neurology 1998;50:858-63.
3. Hely MA, Morris JG, Reid WG, et al. The Sydney multicentre study of Parkinson's disease: a randomized, prospective five year study comparing low dose bromocriptine with low dose levodopacarbidopa. J Neurol Neurosurg Psychiatr 1994;57:903-10.
4. Montastruc JL, Rascol O, Senard JM, Rascol A. A randomized controlled study comparing bromocriptine to which levodopa was later added, with levodopa alone in previously untreated patients with Parkinson's disease: a five year follow up. J Neurol Neurosurg Psychiatry 1994;57:1034-8.
5. Weiner WJ, Factor SA, Sanchez-Ramos JR, et al. Early combination therapy (bromocriptine and levodopa) does not prevent motor fluctuations in Parkinson's disease. Neurology 1993;43:21-7.
6. Piercey MF, Camacho-Ochoa M, Smith MW. Functional roles for dopamine-receptor subtypes. Clin Neuropharmacol 1995;18 (suppl):S34-S42.
7. Piercey MF, Hoffmann WE, Smith MW, Hyslop DK. Inhibition of dopamine neuron firing by pramipexole, a dopamine D3 receptor-preferring agonist: comparison to other dopamine receptor agonists. Eur J Clin Pharmol 1996;312:35-44.
8. Parkinson Study Group. Safety and efficacy of pramipexole in early Parkinson disease: a randomized dose-ranging study. JAMA 1997; 278:125-30.
9. Guttman M, International Pramipexole-Bromocriptine Study Group. Double-blind comparison of pramipexole and bromocriptine treatment with placebo in advanced Parkinson's disease. Neurology 1997;49:1060-5.
10. Hubble JP, Koller WC, Cutler NR, et al. Pramipexole in patients with early Parkinson's disease. Clin Neuropharmacol 1995;18:338-47.
11. Lieberman A, Ranhosky A, Korts D. Clinical evaluation of pramipexole in advanced Parkinson's disease: results of a double-blind, placebo-controlled, parallel-group study. Neurology 1997;49: 162-8.
12. Molho ES, Factor SA, Weiner WJ, et al. The use of pramipexole, a novel dopamine (DA) agonist, in advanced Parkinson's disease. J Neural Transm 1995;45(suppl):225-30.
13. Begg C, Cho M, Eastwood S, et al. Improving the quality of reporting of randomized controlled trials: The CONSORT statement. JAMA 1996;276:637-9.
14. Parkinson Study Group. DATATOP: a multicenter controlled clinical trial in early Parkinson's disease. Arch Neurol 1989;46:1052-60.
15. Lang AE, Fahn S. Assessment of Parkinson's disease. In: Munsat TL, ed. Quantification of Neurologic Deficit. Boston, MA: Butterworth-Heinemann; 1989:285-309.
16. Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology 1967; 17:427-42.
17. Folstein MF, Folstein SE, McHugh P. Mini-mental state: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-98.
18. Richards M, Marder K, Cote L, Mayeux R. Interrater reliability of the Unified Parkinson's Disease Rating Scale motor examination. Mov Disord 1994;9:89-91.
19. Jette AM, Davies AR, Cleary PD, et al. The Functional Status Questionnaire: reliability and validity when used in primary care. J Gen Intern Med 1986;1:143-9.
20. EuroQol Group. EuroQol - a new facility for the measurement of health related quality of life. Health Policy 1990;12:199-208.
21. Welsh M, McDermott M, Holloway R, et al. Development and testing of the Parkinson's disease quality of life scale: the PDQUALIF [abstract]. Mov Disord 1997;12:836.
22. Department of Health and Human Services. Federal Register Part II. Medicare program; physician fee schedule for calendar year 1995; payment policies and relative value unit adjustments. Washington, DC: Department of Health and Human Services; 1995.
23. 1995 Drug Topics Red Book. Montvale, NJ: Medical Economics Data Company; 1995.
24. US Department of Commerce. 1995 US Statistical Abstract. Washington, DC: Government Printing Office; 1995.
25. Innis RB, Seibyl JP, Scanley BE, et al. SPECT imaging demonstrates loss of striatal monoamine transporters in Parkinson's disease. Proc Natl Acad Sci U S A 1993;90:11965-9.
26. Seibyl JP, Marek KL, Quinlan D, et al. Decreased SPECT [I-123]β-CIT striatal uptake correlates with symptom severity in idiopathic Parkinson's disease. Ann Neurol 1995;38:589-98.
27. Parkinson Study Group. Effects of tocopherol and deprenyl on the progression of disability in ealry Parkinson's disease. N Engl J Med. 1993;328:176-83.
28. Lachin JM, Foulkes MA. Evaluation of sample size and power for analyses of survival with allowance for nonuniform patient entry, losses to follow-up, noncompliance, and stratification. Biometrics 1986;42:507-16.
29. Lee YJ, Ellenberg JH, Hirtz DG, Nelson KB. Analysis of clinical trials by treatment actually received: is it really an option? Stat Med 1991; 10:1595-605.
30. Kalbfleisch JD, Prentice RL. The statistical analysis of failure time data. New York: Wiley; 1980.
31. Efron B, Tibshirani RJ. An introduction to the bootstrap. New York: Chapman and Hall; 1993.
32. Chaudhary MA, Stearns SC. Estimating confidence intervals for cost-effectiveness ratios: an example from a randomized trial. Stat Med 1996;15:1447-58.
33. Przuntek H, Welzel D, Blummer E, et al. Bromocriptine lessens the incidence of mortality in L-Dopa treated parkinsonian patients: prado-study discontinued. Eur J Clin Pharmol 1992;43:357-63.
34. van Dyck CH, Seibyl JP, Malison RT, et al. Age-related decline in striatal dopamine transporter binding with iodine-123-β-CIT SPECT. J Nucl Med 1995;36:1175-1181.
35. Olanow CW. Oxidation reactions in Parkinson's disease. Neurology 1990;40(suppl 3):32-7.
36. Fahn S, Cohen G. The oxident stress hypothesis in Parkinson's disease: evidence supporting it. Ann Neurol 1992;32:804-12.
37. Brazier J, Dixon S. The use of condition specific outcome measures in economic appraisal. Health Econ 1995;4:255-64.
38. Physician's Desk Reference, 1997 Edition. Montvale, NJ: Medical Economics Company; 1997.
39. Powe NR, Griffiths RI. The clinical-economic trial: Promise, problems, and challenges. Control Clin Trials 1995;16:377-94.
40. Mushlin AI, Zwanziger J, Gajary E, Andrews M, Marron R. Approach to cost-effectiveness assessment in the MADIT trial. Am J Cardiol 1997;80:33F-41F.
41. Korczyn AD, Brooks DJ, Brunt ER, Poewe WH, Rascol O, Stocchi F. Ropinirole versus bromocriptine in the treatment of early Parkinson's disease: a 6-month interim report of a 3-year study. Mov Disord 1998;13:46-51.
42. Rascol O, Brooks DJ, Brunt ER, et al. Ropinirole in the treatment of early Parkinson's disease: a 6-month interim report of the a 5-year levodopa-controlled study. Mov Disord 1998;13:39-45.